Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Yeh, Chau Ting ^a,b   Chen, Tiffany ^c   Hsu, Chao Wei ^a   Chen, Yi Cheng ^a   Lai, Ming Wei ^d   Liang, Kung Hao ^d   Chen, Tse Ching ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Chang Gung Children Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; ANTIVIRUS AGENT; VIRUS DNA;

ADULT; AGING; ANTIVIRAL RESISTANCE; ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RISK ASSESSMENT; RISK FACTOR; VIRUS MUTANT; AGE; AGED; BLOOD; GENETICS; INCIDENCE; LIVER TUMOR; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80053174570     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-398     Document Type: Article

References (36)

1. Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006, 101(Suppl 1):S1-6.
2. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res 2006, 71:206-15. 10.1016/j.antiviral.2006.04.003, 16716414.
3. Keeffe EB, Marcellin P. New and Emerging Treatment of Chronic Hepatitis B. Clin Gastroenterol Hepatol 2007, 5:285-94. 10.1016/j.cgh.2006.09.036, 17218162.
4. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterol 2003, 125:1714-22.
5. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, . Adefovir Dipivoxil 437 Study Group Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-16. 10.1056/NEJMoa020681, 12606735, Adefovir Dipivoxil 437 Study Group.
6. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, . BEHoLD AI463022 Study Group A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-10. 10.1056/NEJMoa051285, 16525137, BEHoLD AI463022 Study Group.
7. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B, . ACTG Protocol A5127 Team Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatol 2006, 44:1110-6. ACTG Protocol A5127 Team.
8. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatol 1999, 30:567-72.
9. Lai CL, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003, 36:687-96. 10.1086/368083, 12627352.
10. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatol 2000, 31:1318-26.
11. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001, 107:449-455. 10.1172/JCI11100, 199250, 11181644.
12. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297. 10.1016/S0016-5085(03)00939-9, 12891527.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL, . Adefovir Dipivoxil 438 Study Group Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-51. 10.1053/j.gastro.2006.09.020, 17087951, Adefovir Dipivoxil 438 Study Group.
14. Delaney WE. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemotherapy 2007, 59:827-32.
15. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006, 44:1656-65. 10.1002/hep.21422, 17133475.
16. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R, . AI463026 BEHoLD Study Group Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039-49. 10.1053/j.gastro.2006.04.007, 16762627, AI463026 BEHoLD Study Group.
17. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, . Globe Study Group Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-88. 10.1056/NEJMoa066422, 18094378, Globe Study Group.
18. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006, 20:1951-4. 10.1097/01.aids.0000247116.89455.5d, 16988516.
19. Lacombe K, Ollivet A, Gozlan J, Durantel S, Tran N, Girard PM, Zoulim F. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006, 20:2229-31. 10.1097/01.aids.0000252061.35422.84, 17086064.
20. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, . Cirrhosis Asian Lamivudine Multicentre Study Group Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-31. 10.1056/NEJMoa033364, 15470215, Cirrhosis Asian Lamivudine Multicentre Study Group.
21. Choi MS, Yoo BC. Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver 2010, 4:15-24. 10.5009/gnl.2010.4.1.15, 2871615, 20479908.
22. Elefsiniotis I, Buti M, Jardi R, Vezali E, Esteban R. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. Eur J Intern Med 2009, 20:478-81. 10.1016/j.ejim.2008.12.013, 19712848.
23. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. Intervirology 2008, 51:385-93. 10.1159/000203283, 19229115.
24. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res 2010, 40:145-52. 10.1111/j.1872-034X.2009.00582.x, 19788684.
25. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009, 101:1066-82. 10.1093/jnci/djp180, 2720989, 19574418.
26. Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007, 132:543-50. 10.1053/j.gastro.2006.12.001, 17258721.
27. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133:1445-51. 10.1053/j.gastro.2007.08.079, 17983801.
28. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48:747-55. 10.1016/j.jhep.2008.01.027, 18331765.
29. Karatayli E, Karayalçin S, Karaaslan H, Kayhan H, Türkyilmaz AR, Sahin F, Yurdaydin C, Bozdayi AM. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007, 12:761-8.
30. Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, Botta D, Thibault V, Khiri H, Tamalet C. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 2006, 11:1103-6.
31. Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010, 15(3 PtB):471-5.
32. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48:88-98. 10.1002/hep.22295, 18537180.
33. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990, 343:457-61. 10.1038/343457a0, 2153938.
34. Lauer U, Weiss L, Hofschneider PH, Kekule AS. The hepatitis B virus pre-S/S(t) transactivator is generated by 3' truncations within a defined region of the S gene. J Virol 1992, 66:5284-9. 289082, 1323694.
35. Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 2009, 14:249-61.
36. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008, 13:875-9.